Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers

NCT07686367 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

NIH

Sponsor class

Conditions

Metastatic Myxoid Liposarcoma
Metastatic Synovial Sarcoma
Unresectable Myxoid Liposarcoma
Unresectable Synovial Sarcoma

Interventions

BIOLOGICAL: Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

National Cancer Institute (NCI)